Wells Fargo Finally Warms to Oscar Health, but Has the Stock Already Sprinted Past the Finish Line?

Shares surged 14.1% to $23.39 on June 4 after Wells Fargo analyst Stephen Baxter abandoned his bearish stance on Oscar Health, upgrading the stock from Underweight (essentially "sell") to Equal Weight ("hold") and nearly doubling his price target from $11 to $20. The irony: the stock has already blown past that new target, raising the question of whether Wall Street's skeptics are catching up to a story the market already priced in.

• A Former Bear Capitulates — But Still Isn't Bullish. Baxter said Wells Fargo is "increasingly comfortable with the trajectory of the exchange market in 2026, though visibility remains low beyond that period."

The firm's review of regulatory filings found that enrollment and cost outcomes on the ACA exchanges are trending better than expected, with the industry showing material improvement in the share of premiums spent on medical claims. But Equal Weight is neutral — it signals Wells Fargo no longer expects Oscar to underperform, not that it sees big upside from here. Barclays, by contrast, recently raised its price target on Oscar to $30.

• A Blowout Quarter Backs the Bull Case. Oscar posted $679 million in net income — $2.07 per share — in Q1 2026, nearly 2.5 times the year-ago period's $275.3 million.

Membership hit roughly 3.2 million (up 56% year-over-year), the medical loss ratio — the share of premiums spent on medical claims — improved to 70.5% from 75.4%, and revenue surged 53% to $4.6 billion. That Q1 profit alone exceeded the company's full-year operating earnings guidance of $250–$450 million, though management cautioned that costs rise in later quarters.

• Florida Concentration and Subsidy Risk Cloud the Outlook. Florida, Oscar's most important state, represents roughly 64% of premiums but has seen membership decline 13.5% year-over-year. The expiration of enhanced premium tax credits — government subsidies that made marketplace plans cheaper — is expected to drive natural membership churn. Management noted the transition from 3.4 million to 3.2 million members, and expects to start Q3 with about 3 million paid members.

• The Stock Is Running Well Ahead of Analyst Consensus. At $23.39, Oscar trades above virtually every analyst target. Across 18 analysts, the average price target stands at just $19.93, implying roughly 14% downside.

The stock trades at roughly 0.5x trailing revenue, below the 0.7x peer average — cheap by insurance standards, but only if profitability proves durable beyond a seasonally favorable first quarter.

Bottom line: Wells Fargo's upgrade validates Oscar's turnaround but arrives after the stock has already rallied 43% year-to-date. Investors buying here are betting that a single blockbuster quarter marks the start of a trend, not its peak.